FEMY · Femasys Inc · Metrics
$2.05
-0.05 (-2.38%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 8, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$20.77M
Shares
8.38M
Volume · Oct 2
252.64K
Avg daily vol (3M)
714.62K
FEMY metrics
59 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$2.10
Market cap
$20.77M
Price action
20 metricsPrice change (1W)
-16.3%
Price change (30D)
-30.3%
Price change (3M)
-50.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
109.8%
Annualized volatility (3M)
111.6%
Beta
—
RSI (14D)
34.0
Price vs SMA 50
-21.9%
Price vs SMA 200
—
Avg volume (3M)
714,609
Relative volume
0.2
Average dollar volume
$1.95M
Company
3 metricsSector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
8.38M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.0×
reciprocal yield 11.1%
P / book
5.2
reciprocal yield 19.4%
FCF yield
-87.0%
TTM · current market cap
Buyback yield
1.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-56.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-03-21
Profitability
9 metricsGross margin
—
Operating margin
-763.9%
Trailing 12 months
Net margin
-511.8%
Gross profit (TTM)
$705,869
Operating profit (TTM)
−$17.57M
Net income (TTM)
−$11.77M
Trailing 12 months
Diluted EPS (TTM)
$-2.95
FCF margin
-786.0%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-18.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.30M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+132.5%
Year over year · more shares
Revenue CAGR (3Y)
+23.9%
Revenue CAGR (5Y)
+17.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-291.9%
Return on assets
-95.8%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$17.23M
Free cash flow (TTM)
−$18.07M
Quick ratio
0.6
Interest coverage
-13.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.44M
Latest balance sheet
Cash & equivalents
$1.44M
Total assets
$12.29M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$17.65M
Capital expenditures (TTM)
$422,713
R&D (TTM)
$6.45M
SG&A (TTM)
—
Stock compensation (TTM)
$603,365
R&D / revenue
280.5%
Stock compensation / revenue
26.2%
Ownership (13F)
3 metrics13F filers
18
13F filer change QoQ
-18
Institutional ownership
24.7%
Short interest
3 metricsShort interest
7.3%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
59 / 100
Insider activity
2 metricsNet insider buying (90D)
$134,000
Insider-sentiment score
91 / 100
Risk flags
1 metricsGoing concern
—